Consolidative donor lymphocyte infusion following HLA-mismatched allogeneic hematopoietic stem cell transplantation from haploidentical donor for hematological malignancy in non-remission.

Consolidative donor lymphocyte infusion following HLA-mismatched allogeneic hematopoietic stem cell transplantation from haploidentical donor for hematological malignancy in non-remission. - Consolidative DLI following haploidentical HSCT for hematological malignancy in non-CR.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043766

Enrollment

Registered

2021-03-30

Start date

2021-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy in non-remission at haploidentical transplantation

Interventions

Consolidative DLI at 45 - 60 days from haploidentical transplantation. DLI dose is 1*10E5 CD3+ cells/kg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who underwent haploidentical transplantation for hematological malignancy in non-remission or hematological remission with positive MRD (molecular non-remission). 2. Patients who achieved hematological remission at day 30 from transplantation. 3. Patients who have a donor providing lymphocytes for DLI. 4. Patients who are 16 to 70 years old. 5. Patients in performance status of 0-2. 6. Patients whose major organ functions are preserved.

Exclusion criteria

Exclusion criteria: 1. Patients with poorly controlled active infection. 2. Patients with Grade II-IV acute GVHD. 3. Patients with serious mental disorder.

Design outcomes

Primary

Measure	Time frame
Disease-free survival rate at 1 year from transplantation	—

Countries

Japan

Contacts

Public ContactShinichi Kako

Jichi Medical University Saitama Medical Center Division of Hematology

shinichikako@asahi-net.email.ne.jp+81-48-647-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026